Abstract: The present invention relates to novel heparin-nitroxide derivatives comprising heparin and at least two and more nitroxides/polynitroxide radicals that are covalently coupled to heparin by derivatisation of glycosaminoglycan carboxyl or amino groups. The heparin-nitroxide derivatives are useful as therapeutic or diagnostic agents. This invention further concerns novel methods for the production of the heparin-nitroxide agents, and methods of their uses for specifically targeting and labelling of biological vessels. The inventions also suggest the uses of the heparin-nitroxide derivatives for treatment of oxidative stress-mediated diseases. Furthermore, the heparin-nitroxide derivatives according to the present invention are in particular useful for electron paramagnetic resonance imaging (EPRI), for magnetic resonance imaging (MRI), and for preservation of biological transplants.

Abstract: A patient in need of nitroglycerin therapy is treated with nitroglycerin and agent that prevents inhibition of or reverses inhibition of mtALDH and/or the generation of reactive oxygen species from mitochondria, e.g., a mitochondrial antioxidant which is not a reducing agent or a dithiol, e.g., ebselen or uric acid. Nitroglycerin dosage can be regulated and inhibiting agent dosage can be regulated and tolerance postponed by monitoring blood level of active mtALDH and dosing in response to determined level of active mtALDH.

Abstract: A patient in need of nitroglycerin therapy is treated with nitroglycerin and agent that prevents inhibition of or reverses inhibition of mtALDH and/or the generation of reactive oxygen species from mitochondria, e.g., a mitochondrial antioxidant which is not a reducing agent or a dithiol, e.g., ebselen or uric acid. Nitroglycerin dosage can be regulated and inhibiting agent dosage can be regulated and tolerance postponed by monitoring blood level of active mtALDH and dosing in response to determined level of active mtALDH.